Skip to main content

Malin Life Sciences Holdings Ltd's Form 4 filing

Poseida Therapeutics, Inc. (PSTX) · filed Nov 23, 2021

Accession no.
0001104659-21-143142
Filed
Nov 23, 2021
Trade date
Nov 19-23, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $181.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Malin Life Sciences Holdings LtdCIK 000168513810% Owner, Other: Common director with Issuer

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 19, 2021COMMON STOCKPPurchaseAcquired+11,104$7.44F1+$82,613.769,578,605Direct
Nov 23, 2021COMMON STOCKPPurchaseAcquired+14,625$6.77F1+$99,011.259,593,230Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The reported prices in Column 4 are weighted average prices. Those shares were purchased in multiple transactions at per share prices ranging from $7.37 to $7.54 on 11/19/2021; and $6.695 to $6.89 on 11/23/2021. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)